Sanofi gets US FDA OK for talking injection device
The product - Auvi-Q (epinephrine injection, USP) – is used for the treatment of allergic reactions in people who are at risk for or have a history of anaphylaxis.
The idea is that under such life-threatening circumstances the device talks users or caregivers through each step of the injection process with audible and visual cues, including a five-second injection countdown and an alert light to signal when the injection is complete.
Sanofi licensed North American commercialization rights to Auvi-Q from Intelliject, which has retained commercialization rights for the rest of the world.
Bryan Downey, Vice President, Auvi-Q, Sanofi US, said: “With this FDA approval, Auvi-Q will become the first-and-only epinephrine auto-injector that talks users through each step of the injection process,”
The French drugmaker licensed North American commercialization rights to Auvi-Q from Intelliject, which has retained commercialization rights for the rest of the world.
